Abstract：Objective To understand the clinical characteristics, treatment and prognosis of patients with infective endocarditis (IE), and provide reference for the early diagnosis and treatment of IE. Methods Clinical data, isolated pathogens, treatment and prognosis of patients with IE diagnosed in Xiangya Hospital from January 2009 to December 2009 were analyzed retrospectively. Results A total of 430 patients who met the diagnostic criteria of IE were included, most of them were males (n=289, 67.2%). The average age was (40.3±15.1) years. 284 patients (66.0%) had no underlying heart disease, 146 (34.0%) had underlying heart disease, 115 (26.7%) had congenital heart disease, 23 (5.3%) had rheumatic heart disease, and 8 (1.9%) had non-rheumatic heart valve disease. The main clinical manifestations of IE were fever (n=336, 78.1%), anemia (n=381, 88.6%) and heart murmur (n=383, 89.1%); the most common complication was embolism (21.4%), followed by heart failure (18.8%). There were 151 cases of valve prolapse, 88 cases of valve stenosis, 347 cases of valve insufficiency, mostly were aortic valve insufficiency (n=134), 72 cases were with two or more valve insufficiency; positive rate of blood culture was 44.9%, Streptococcus spp.was the most common pathogen (119 strains, 61.7%), followed by Staphylococcus spp., (41 strains, 21.2%). 319 patients (74.2%) with IE were operated, mortality was 10.2%, the recovery rate of patients receiving drug therapy combined with surgery was higher than that of patients only receiving drug therapy(95.3% vs 64.9%,P<0.001). Conclusion At present, IE is common in patients with underlying heart disease, the most common pathogen is Streptococcus spp., anti-infective treatment is the basis of IE treatment, early surgery can reduce the in-hospital mortality.
Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States From 2000 to 2011[J]. J Am Coll Cardiol, 2015, 65(19):2070-2076.
[2]
Habib G, Lancellotti P, Iung B. 2015 ESC Guidelines on the management of infective endocarditis:a big step forward for an old disease[J]. Heart, 2016, 102(13):992-994.
Fernández-Hidalgo N, Almirante B, Tornos P, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis[J]. Clin Infect Dis, 2008, 47(10):1287-1297.
[12]
DeSimone DC, Tleyjeh IM, Correa de Sa DD, et al. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN[J]. Am Heart J, 2015, 170(4):830-836.
[13]
Netzer RO, Zollinger E, Seiler C, et al. Infective endocarditis:clinical spectrum, presentation and outcome. An analysis of 212 cases 1980-1995[J]. Heart, 2000, 84(1):25-30.
[14]
Şimşek-Yavuz S, Şensoy A, Kaşıkçıogğlu H, et al. Infective endocarditis in Turkey:aetiology, clinical features, and analysis of risk factors for mortality in 325 cases[J]. Int J Infect Dis, 2015, 30:106-114.
[15]
Garg N, Kandpal B, Garg N, et al. Characteristics of infective endocarditis in a developing country-clinical profile and outcome in 192 Indian patients, 1992-2001[J]. Int J Cardiol, 2005, 98(2):253-260.
[16]
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis:diagnosis, antimicrobial therapy, and management of complications:a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association:endorsed by the Infectious Diseases Society of America[J]. Circulation, 2005, 111(23):e394-e434.
[17]
Vilacosta I, Graupner C, San Román JA, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis[J]. J Am Coll Cardiol, 2002, 39(9):1489-1495.
[18]
Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis:a consequence of medical progress[J]. JAMA, 2005, 293(24):3012-3021.
[19]
Toyoda N, Chikwe J, Itagaki S, et al. Trends in infective endocarditis in California and New York State, 1998-2013[J]. JAMA, 2017, 317(16):1652-1660.
[20]
Bjørkeng EK, Hjerde E, Pedersen T, et al. ICESluvan, a 94-Kilobase Mosaic integrative conjugative element, conferring interspecies transfer of VanB-type glycopeptide, resistance, a novel bacitracin resistance locus, and a toxin-, antitoxin stabilization system[J]. J Bacteriol, 2013, 195(23):5381-5390.
[21]
Park C, Nichols M, Schrag SJ. Two cases of invasive vancomycin-resistant group B streptococcus infection[J]. N Engl J Med, 2014, 370(9):885-886.
